Intra-Cellular Therapies (ITCI) Starts April Trading Flat, Holding Near 52-Week High
Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) kicked off trading on April 1st with its stock price holding steady, showing no change at $131.87 as of the 4:00:01 PM EDT market open timestamp. This flat performance comes after the stock closed the previous session at the exact same price, $131.87.
The stability is particularly noteworthy as ITCI shares are hovering just shy of their 52-week high of $131.98. This indicates the stock is maintaining its peak valuation territory achieved over the last year, a significant climb from its 52-week low of $64.09. The listed opening price for the day was slightly higher at $131.92, though the day’s range reported in the early snapshot remained tight at $131.87 – $131.87.
Market capitalization for the company stands at approximately $14.047 billion based on intraday data. While the chart indicated “Volume Not Available” for the current session at the time of the snapshot, the reported volume figure (potentially from the previous day) was a substantial 16,042,154 shares, far exceeding the average volume of 3,630,696 shares, suggesting heightened recent activity.
From a financial metrics perspective, Intra-Cellular Therapies currently has a negative Earnings Per Share (EPS TTM) of -$0.73, resulting in an unavailable Price-to-Earnings (PE) ratio. The stock displays a Beta (5Y Monthly) of 0.46, suggesting lower volatility compared to the broader market. The company does not currently offer a dividend.
Looking ahead, market participants may anticipate the next earnings announcement, estimated to fall between May 5, 2025, and May 9, 2025, according to the provided data, though investors often look towards quarterly updates typically expected around May 2024. The current 1-year analyst target estimate for ITCI stock is pegged at $132.00.
